LHON (Leber hereditary optic neuropathy) is a maternally inherited disease that leads to sudden loss of central vision at a young age. There are three common primary LHON mutations, occurring at positions 3460, 11778 and 14484 in the human mtDNA (mitochondrial DNA), leading to amino acid substitutions in mitochondrial complex I subunits ND1, ND4 and ND6 respectively. We have now examined the effects of ND6 mutations on the function of complex I using the homologous NuoJ subunit of Escherichia coli NDH-1 (NADH:quinone oxidoreductase) as a model system. The assembly level of the NDH-1 mutants was assessed using electron transfer from deamino-NADH to the 'shortcut' electron acceptor HAR (hexammine ruthenium), whereas ubiquinone reductase activity was determined using DB (decylubiquinone) as a substrate. Mutant growth in minimal medium with malate as the main carbon source was used for initial screening of the efficiency of energy conservation by NDH-1. The results indicated that NuoJ-M64V, the equivalent of the common LHON mutation in ND6, had a mild effect on E. coli NDH-1 activity, while nearby mutations, particularly NuoJ-Y59F, NuoJ-V65G and NuoJ-M72V, severely impaired the DB reduction rate and cell growth on malate. NuoJ-Met 64 and NuoJ-Met 72 position mutants lowered the affinity of NDH-1 for DB and explicit C-type inhibitors, whereas NuoJ-Y59C displayed substrate inhibition by oxidized DB. The results are compatible with the notion that the ND6 subunit delineates the binding cavity of ubiquinone substrate, but does not directly take part in the catalytic reaction. How these changes in the enzyme's catalytic properties contribute to LHON pathogenesis is discussed.
INTRODUCTION
LHON (Leber hereditary optic neuropathy) is a maternally inherited human disease causing acute to subacute bilateral painless loss of central vision in young adults, with male predominance. After the acute phase, optic nerve atrophy and centrocaecal absolute scotoma develop within weeks in one eye, followed by the other eye after a mean interval of 2 months [1] . The final visual outcome varies, and patients occasionally experience a marked visual recovery after the acute phase, both being dependent on the genotype [2] . The underlying genetic cause in LHON is a mutation in the mitochondrial genome. The first reported mutation linked to LHON was G11778A [3] , and this and two other missense mutations, G3460A and T14484C, currently account for 96 % of all patients diagnosed [4] , so that they are classified as common primary mutations.
Mitochondrial NADH:ubiquinone oxidoreductase (complex I; EC 1.6.5.3) extracts electrons from NADH and channels them through FMN and a set of serially arranged iron-sulfur clusters to the reduction site of the lipophilic electron acceptor ubiquinone [5] . The energy liberated in this electron transfer is used to drive proton pumping across the mitochondrial inner membrane with a stoichiometry of 4H + /2e − [6] . It is a multi-subunit enzyme with 45 dissimilar proteins [7] , 14 of which constitute the evolutionally conserved catalytic core, which is also found in NDH-1 (bacterial NADH:quinone oxidoreductase), the bacterial counterpart of the mitochondrial complex I, see [8] for a review.
In mitochondrial complex I, seven of these 14 core subunits are encoded by the mitochondrial genome and synthesized within the organelle [9] . All of these seven subunits, designated ND1-ND6 and ND4L, are integral membrane proteins having 3-14 transmembrane segments [10] .
The common primary LHON mutations occur in three subunits of complex I, namely ND1, ND4 and ND6, all of which belong to the membrane domain of the enzyme. Several additional LHON-associated replacement mutations have been found in other mitochondrially encoded subunits of complexes I, III, IV and F 1 F o -ATPase-synthase [11] . Taking all the known LHON mutations into account, it appears that the ND1 and ND6 genes are the main 'hot spots' for such mutations [12, 13] , since a total of 16 of their codons have been identified as being associated with LHON (Mitomap, May 2007; http://www.mitomap.org). Interestingly, many of the pathogenic ND6 subunit mutations are located in the relatively highly conserved N-terminal region within its third transmembrane helix ( Figure 1 ).
Several hypotheses have been proposed regarding the primary cause of the disease phenotype. These include mild impairment of mitochondrial respiration due to a complex I defect, as found in the ND1-A52T and ND4-R340H mutations [14] but not in ND6-M64V [15, 16] . A defect in ATP production with unaltered ATP content has been found in trans-mitochondrial hybrid cell lines carrying any of the common LHON mutations [17, 18] . Increased production of ROS (reactive oxygen species) or increased sensitivity to oxidative stress has been found in an The predicted transmembrane helix in the E. coli sequence is underlined [52] . Highly conserved amino acids are highlighted in grey. The symbol '᭡' denotes residues for which site-directed mutants were constructed in the present study. The uppermost line shows substitutions associated with diseases [12, 53, 54] . The GenBank ® accession numbers for the sequences are (from top to bottom) ABA08023 (human), AAV88355 (bovine), NP_007573 (Alligator mississippiensis), NP_059342 (zebrafish), CAC28088 (Yarrowia lipolytica), YP_271941 (Montastraea franksi), CAA60351 (maize chloroplast), P29922 (P. denitrificans), AAA97947 (Thermus thermophilus) and NP_416783 (E. coli). The alignment was performed with the ClustalW program.
ND1-A52T and ND4-R340H mutant cybrid neuronal cell model [19] , whereas ROS production was not markedly increased in an ND6-M64V mutant cell line [20] . Cell death in LHON appears to occur by an apoptotic mechanism [21, 22] , but it remains obscure how the apoptotic wave of cell death is initiated exclusively in the retinal ganglion cells, especially in the case of the mild ND6-M64V mutation.
The mitochondrial genome accumulates mutations at a rate approximately one order of magnitude faster than the nuclear genome, and it is difficult to distinguish between rare haplogroupspecific variants and true pathogenic LHON mutations [23] . The pathogenic mutations are also frequently accompanied by other genetic alterations in mtDNA (mitochondrial DNA), and the contribution of individual mutations to the clinical phenotype and the biochemical defect may be difficult to establish. It is also very difficult to introduce site-specific mutations into the mitochondrial genome, so that we employed a bacterial homologue of complex I, the NDH-1 of Escherichia coli, as a model system for studying the effects of LHON and other mutations in the NuoJ subunit, the bacterial counterpart of ND6, on the function of the enzyme. The method allows us to examine the putatively pathogenic mutations against a truly neutral background and to explore their effects on the enzyme's catalytic turnover in detail.
A bacterial system has been employed on several occasions to model disease mutations. During the execution of the present study, which started during our endeavours with site-directed mutagenesis of the NuoK subunit [24] , Kao et al. [25] reported on the modelling of mutations in the NuoJ subunit in E. coli, and our study, carried out using the methodology we had developed for NuoK [24] , may also be partly regarded as an extension of the experiments of Kao et al. [25] on NuoJ. We have now analysed the E. coli equivalent of the common LHON mutation 14484/ ND6-M64V as well as several other point mutations in its vicinity. This is important, because current knowledge of the pathophysiology of LHON is insufficient and the delineation between pathogenic mutations and polymorphism is difficult, so that the purported role of some mtDNA mutations in the development of LHON has recently been challenged [26] . 
Mutagenesis
A series of site-directed mutants was generated employing the same strategy as was applied earlier to the study of mutations in the NuoK subunit of E. coli NDH-1, an equivalent of the ND4L subunit of complex I [24] . The point mutations listed in Table 1 were introduced into pJK [24] using the QuikChange ® XL mutagenesis kit (Stratagene) according to the manufacturer's instructions, followed by DNA sequencing of the construct. The oligonucleotides used in mutagenesis are listed in Supplementary • C) when the attenuance at 600 nm (D 600 ) reached 0.1-0.4, cooled and washed with 50 mM Mes/KOH (pH 6.5), 2.5 mM EDTA and 0.2 mM PMSF. The washed cells were used for membrane preparation as described by Leif et al. [28] , except that 50 mM Mes/KOH (pH 6.5), 0.2 mM PMSF, 5 mM MgSO 4 and 10 µg/ml DNase I were used during the French press treatment. Unbroken cells and debris were removed by centrifugation (4200 g, 20 min), only the supernatant was used for ultracentrifugation (180 000 g, 65 min) and the membranes were suspended in 50 mM Mes/KOH (pH 6.5) containing PMSF as above, to approx. 0.5 ml/g of initial cell weight. Membrane samples for the inhibitor titration experiments were prepared as described in [29] . The protein concentration in the membrane preparations was assessed by the method of Lowry et al. [30] . Growth on malate was determined as the final attenuance of the culture at 600 nm (D 600 ) after 24 h of growth in malate-YE medium at 37
• C.
Activity measurements
E. coli possesses two NADH:quinone oxidoreductases, NDH-1 and NDH-2. The former is an equivalent of complex I, while the latter is a single-subunit enzyme that, although catalysing electron transfer from NADH to ubiquinone, does not couple the electron transfer activity with proton translocation across the membrane or to the generation of a membrane potential [31] . The two E. coli NADH oxidases can be distinguished from each other in activity assays by employing the non-physiological NADH analogue d-NADH as a substrate, since this serves as an equally good electron donor for NDH-1 as NADH, whereas NDH-2 is unable to oxidize it. Accordingly, d-NADH was used as a substrate to measure NDH-1-dependent activities, while NADH was employed to assay the combined NDH-1 and NDH-2 capacity, which corresponds better to the in vivo situation during bacterial growth. The activity assays were performed on a dual-wavelength spectrophotometer as previously described [24] , with the modifications that the d-NADH:DB oxidoreductase assays were performed with freshly prepared membrane samples (0.1 mg/ml membrane protein), 0.5 mg/ml soya bean phospholipid and 90 µM d-NADH. Six DB concentrations, ranging from 50 to 600 µM, were used and three parallel experiments were performed at each concentration. The rates of DB reduction in the concentration range between 0.5 and 45 µM were estimated from the progress curve throughout the course of a complete reaction (in triplicate), the initial DB concentration being 30-45 µM. Three to five colonies for each mutant or control were analysed independently. The VNA sensitivity at 100 µM DB was tested by adding VNA to a final concentration of 400 µM after recording the initial DB-reductase activity for 1-2 min. For the d-NADH:HAR activity, the previously used annonin was replaced by 400 µM VNA. In the sensitivity tests, the inhibitors dissolved in ethanol or DMSO to a final concentration of 30-400 µM VNA, 0.5-20 µg/ml annonin, 0.5-19 µM piericidin A, 5-100 µM stigmatellin or 5-100 µM myxothiazol (or an equal amount of ethanol or DMSO) were added before DB and the assays were conducted similarly to the d-NADH:DB oxidoreductase assays in all other aspects. The DB concentration was determined spectrophotometrically using a molar absorption coefficient (ε) of 14.0 mM −1 · cm −1 at 278 nm.
Statistics
Student's t test for independent samples was used to compare two groups. For multiple comparisons, one-way ANOVA followed by the Dunnett's test was used. Curves were fitted to the kinetic equation with Sigmaplot 9.0 (Systat Software, Erkrath, Germany).
RESULTS

Growth and NADH oxidation capacity
On the basis of our previous experiments on NuoK mutagenesis in E. coli, the inability to grow on malate is a useful measure of the energy-conserving function of NDH-1 [24] . Therefore the effects of mutations on complex I activity were first evaluated by testing their effect on cell growth in a minimal medium where malate was the main carbon source. The results, depicted in Figure 2 , show that there is a positive sigmoidal correlation between d-NADH oxidase activity and cell growth measured as attenuance at 600 nm (r = 0.796, P < 0.001). Interestingly, the growth of the double mutant M64V/M72A on malate as the main carbon source, and also the d-NADH:O 2 activity, were lower than for either mutant alone (Table 2) . Among the set of NuoJ mutants produced, Y59F and V65G exhibited a knockout-like growth pattern, while the final D 600 of the M72V mutant in the malate-YE medium was only slightly higher (Table 2 ). To test whether the poor growth capacity of these mutants was due to a deficiency in the respiratory chain downstream from the NDH-1 site or to NDH-1 itself, their NADH:O 2 activities were measured ( Table 2) . Subtraction of the d-NADH:O 2 activity from the NADH:O 2 activity gives an estimate of the NDH-2-linked respiration bypassing the NDH-1 coupling site, and this turned out to be even higher in the Y59F, V65G and M72V mutants than in the controls (results not shown), demonstrating that, apart from NDH-1, the respiratory complexes were functioning normally in these mutants.
Expression and assembly
The HAR reductase activity (d-NADH:HAR) in the membranes (Table 2 ) was used to estimate the level of expressed and assembled NDH-1, since its loss through nuoJK knockout could be restored by complementation in trans [24] . Despite the impaired malate growth, mutants Y59F and M72V exhibited considerable d-NADH:HAR reductase activity, similar to the control or mutants such as Y59C that grew much better on malate. Even in the case of V65G, the poorest-growing mutant, the d-NADH:HAR reductase activity was higher than in the double mutant M64V/M72A, although the latter, but not the former, grew reasonably well on malate ( Table 2) . The results also revealed great variability in expression and assembly levels between membrane batches of individual mutants. Due to this observation, the d-NADH:DB activity of each batch of membranes was normalized to the corresponding HAR reduction activity (by taking the activity ratio) in order to better reveal changes in enzyme catalysis.
Ubiquinone reduction and binding
The d-NADH:DB reductase activity and its dependence on the electron acceptor concentration were measured in isolated membranes from the various strains (Table 3) . Complementation of the knockout with wild-type nuoJK construct (control in Table 3 ) resulted in 34 % of the assembly normalized NDH-1 activity in the parent strain GV102 under same conditions [29] . The reason for this is currently unsolved, but it may partly be due to non-synchronized expression and assembly of NDH-1 subunits from the nuo-operon and the plasmid. Assembly-normalized NDH-1 activities were, however, constant in control complementations with the nuoJK expression plasmid introducing a C-terminal His 6 tag into NuoK, present in all NDH- 1 enzymes analysed in the present study or with a plasmid where the original stop codon was reintroduced into nuoK (M. Kervinen, unpublished work). Therefore we consider it justified to use this system to evaluate the effects of site-directed mutations on NDH-1, and the results obtained with different mutants were compared with the wild-type complementation throughout the present study.
As compared with the method used by us previously [24] , the changes to the membrane preparation procedure (omission of EDTA, addition of Mg 2+ and avoidance of freezing of the sample before the assay) resulted in higher respiratory chain activities and made it possible to perform more detailed analyses of NDH-1 function. The results demonstrated that one mutant, V65G, was practically devoid of d-NADH:DB reductase activity (5.5 + − 0.6 nmol · min −1 · mg −1 of protein at 100 µM DB compared with 196 + − 22 nmol · min −1 · mg −1 of protein in the control), and that this was not stimulated by higher DB concentrations (results not shown). No accurate analysis of the DB reduction kinetics could be performed in this case, however. Mutant Y59F exhibited the lowest (corrected) V max value, while the V max /HAR ratio was also significantly decreased in mutants M64C, M72V and M72C (Table 3 ). The same pattern was observed in the assembly-corrected d-NADH oxidase activities in these mutants (with endogenous ubiquinone as a substrate), the ratios of d-NADH:O 2 activity to the HAR reduction rate being 47, 38 and 51 % of the control respectively. Unlike the other mutants and the control, Y59C and Y59F showed higher NDH-1 activities with the endogenous electron acceptor than with DB as compared with the wild-type control [93 % of wild-type activity with endogenous ubiquinone compared with 73 % (V max /HAR) with DB, and 45 % with endogenous ubiquinone compared with 38 % with DB, in Y59C and Y59F respectively].
An interesting finding was that some mutations led to a clear substrate inhibition by oxidized DB (Figure 3 ). This was analysed by fitting the data to the equation:
where K s is the equilibrium constant for binding of a second substrate molecule to the active site of the enzyme-substrate complex [32] . The results are listed in analogue (Table 3) , suggesting somewhat lower affinity for the physiological electron acceptor as well. Mutations at Tyr 59 did not have a significant effect on the K m value, but, in contrast, showed the largest increase in sensitivity to substrate inhibition by DB, the Y59C mutant having the clearest effect (Table 3 and Figure 3 ). The double mutant M64V/M72A also showed some increase in sensitivity to substrate inhibition, higher than with either of the mutations alone, but the difference in K s was not statistically significant as compared with the control. Additionally, all position Met 72 substitutions, which led to an increased K m for DB, also showed a tendency for an increase in K s .
The d-NADH:HAR, d-NADH:O 2 , NADH:O 2 and d-NADH:DB activities in the control and the mutants growing poorly on malate, namely Y59F, V65G and M72V, were also analysed in membranes from cells grown on LB medium and were very similar to the results for the respective membrane batches prepared from cells grown in the malate-YE medium, as listed in Tables 2 and 3 .
Inhibitor-sensitivity
The sensitivity of the d-NADH:DB oxidoreductase activity to 400 µM VNA in the mutants did not differ much from the wildtype (percentage inhibition of the initial rate was 73-84 %), except perhaps in Y59F (66-74 %). Titration experiments in the presence of 100 µM DB and 90 µM d-NADH showed, however, that the IC 50 for VNA in mutant Y59F was very similar to the control value, 56 and 62 µM respectively. We selected M72V, the counterpart of the disease-associated ND6-A72V mutant, for further inhibitorsensitivity experiments because this mutant showed the largest decrease in DB affinity. Sensitivity was tested for class I/A-type and C-type inhibitors and for stigmatellin and myxothiazol, which interact at or near the ubiquinone-binding site(s). The results indicate a clear increase in the IC 50 value of mutant M72V for both annonin and VNA, but not for piericidin A, stigmatellin or myxothiazol (Table 4) . It should be noted here that an equal amount of membrane protein was used in the cuvette for each of the mutants or control and excess phospholipid was added in both the DB binding and inhibitor-sensitivity experiments in order to eliminate the effect of changes in lipid content between separate samples.
DISCUSSION
Despite an abundance of research into the pathophysiology of LHON, the underlying cause of the onset of neuronal cell death remains obscure and the biochemical defects at the level of complex I are controversial. We have developed a disease model in E. coli in which we can estimate and compare the effects of different LHON mutations (including the rare ones) on complex I activity against a genetically neutral background without the contribution of other mitochondrial or nuclear DNA mutations. A similar approach was used recently to investigate the effects of amino acid changes within the ND1 subunit causing MELAS (mitochondrial encephalomyopathy, lactic acidosis and stroke like episodes) syndrome [29] . The effect of mutated mtDNA against neutral nuclear background can be studied, even in mammalian cells, using cybrid techniques and haplotype-matched controls, although lack of the possibility of its site-directed mutagenesis remains a shortcoming. A few mtDNA mutations have been found in derivatives of murine cell lines after culturing under conditions selective for defects in cell respiration, and random mutagenesis can be used in combination with production of transmitochondrial cybrids [33, 34] . Human colonocytes from aged individuals harbour mtDNA mutations, and can be studied experimentally in cybrid cells, but they are different from those occurring in proven inherited mitochondrial disease [35] . Therefore focusing on a spectrum of defined mtDNA mutations is difficult on a neutral genetic background when one uses in vitro eukaryotic models. Although restricted to the structural genes of the respiratory enzymes and mainly to the effects expressed at the enzymatic level, use of bacterial models makes it possible to study also more deleterious substitutions than those caused by the naturally occurring mtDNA mutations, and may therefore be a more useful model in elucidating the catalytic function of complex I.
In trans complementation of the nuoJK-knockout strain was used here to introduce several replacement mutations into NuoJ, the E. coli counterpart of human ND6, at sites corresponding to the LHON mutations, residues Tyr 59 , Met 64 and Ala 72 , and in some nearby residues, in order to investigate the effects of these amino acid substitutions on NDH-1 activity. It may be noted here that Kao et al. [25] have recently inserted mutations directly into the nuoJ gene of the E. coli genome. Importantly, the DB reductase activities in the Y59C, Y59F, M64V and V65G generated by Kao et al. [25] and in the present study by means of in trans complementation were comparable, so that it may be concluded that these two methods are equally applicable. In order to understand the nature of the effect these mutations have on the enzyme, we performed a further analysis of the mutants compared with the previous work of Kao et al. [25] by determining the NDH-1-dependent growth phenotype and kinetic parameters for the mutant enzymes in question, and probed the selected mutant enzymes with a series of NDH-1-specific inhibitors.
Substitution of glycine for Val 65 had deleterious effects on NDH-1, in agreement with previous findings (see above), and the NDH-1 activity in this mutant was not ameliorated by higher DB concentrations, which suggests that the defect brought about by the substitution is probably not due to a change in DB affinity, although no detailed analysis of DB binding could be performed. Many of the other mutations generated in the present study affected DB binding by NDH-1. The ubiquinone-binding cavity in complex I is assumed to be large and elongated, harbouring three overlapping inhibitor-binding sites [36, 37] . It has been concluded on the basis of changes in inhibitor affinities in several mutants that the ubiquinone-binding site resides in the contact region between the 49 kDa and PSST (20 kDa subunit of mitochondrial complex I) subunits in the hydrophilic part, or at the interface between the hydrophilic part and the membrane arm, see [38] for a review. Although the location of the ND6 subunit with respect to the hydrophilic part is currently unknown, some evidence for it contributing to ubiquinone binding has been presented. In cybrid submitochondrial particles carrying an A72V mutation in ND6, substrate and product inhibition by DB and decylubiquinol respectively have been observed [39] . Contrary to this, substitutions at Met 72 of E. coli NuoJ in the present study did not cause any substrate inhibition by DB, but instead induced a 1.7-2.0-fold increase in K m for DB and lowered the affinity for binding a second substrate molecule at the active site, as well as affecting inhibitor resistance (Tables 3 and 4 ). There are no clinical studies on ubiquinone binding in the 14484/ND6-M64V mutant, although a change in this was proposed on the basis of changes in inhibitor-sensitivity [40] . The Met 64 residue has been subjected to mutagenesis in E. coli previously, and according to capsaicin inhibition data it is not involved in ubiquinone binding [25] . So whereas reports on the effects on the human enzyme and its bacterial counterpart are discrepant, the present results demonstrate a 1.4-fold increase in the K m for DB in response to the M64V replacement in E. coli (Table 3) .
It is evident that this domain of NuoJ/ND6, which harbours many disease-associated mutations, has some relationship to ubiquinone-binding site(s). In order to understand this relationship better, the mutant with the largest change in ubiquinone affinity, namely NuoJ-M72V, was tested for changes in inhibitor-sensitivity with several classes of complex I inhibitors. Unlike the C-type inhibitor VNA, the inhibitory action of piericidin A, which belongs to class I/type-A, and stigmatellin and myxothiazol did not affect the mutants differently from the controls. Since class I/type-A inhibitors, which are quinone-like, and C-type inhibitors do not compete with each other for binding [36] , it is plausible that the C-type inhibitors are bound more distantly in the ubiquinone cavity, at sites leading to the actual active site. Annonin VI is considered a class I/type-A inhibitor [41] , but in contrast with piericidin A, it was found here to bind to the NuoJ-M72V mutant enzyme with lower affinity than the control (Table 4 ). The apparent discrepancy in binding between these two inhibitors can be explained by the rather long structure of the annonin VI molecule, with the possible protein-interacting atoms well spaced out. Therefore this inhibitor molecule could interact in both type-A and type-C inhibitor-binding domains. This is not in conflict with the previous work of Okun et al. [36] , where displacement of the rather short type-A inhibitor 2-decyl-4-quinazolinyl amine was not observed with the type-C inhibitor CC 44. In conclusion, NuoJ-M72V changes the binding affinity of inhibitors that interact with the type-C binding domain. The stable binding of the ubiquinone head group in NuoJ/ND6 is unlikely to be due to the low magnitude of the DB affinity changes and the inhibitor-sensitivity pattern observed in the present study. More probably, NuoJ/ND6 might be lining the cavity leading to the actual binding site and providing only transitory interaction with the ubiquinone head group (Figure 4) . It was proposed earlier by DeHaan et al. [42] that single amino acid substitutions in ND6 may perturb the secondary structure of the transmembrane helices, thereby causing long-ranging structural derangements. We consider this option unlikely, because none of the mutations introduced should result in steric congestion due to the smaller size of the amino acid introduced as compared with the wildtype, and because the observed changes in inhibitor binding can be assigned to a certain class of inhibitors, whereas larger changes in protein structure would be likely to affect the closely situated type-A inhibitor-binding site as well.
One of the novel findings of the present study is the substrate inhibition by DB in the Y59C mutant. Substrate inhibition by exogenous short-chain ubiquinones [DB, Q 1 (ubiquinone-1) and Q 2 ] has been reported for the LHON-associated ND1-A52T mutation in mitochondrial membrane preparations from lymphoblasts [15] , and in the presence of ND6-A72V substitution (see above). Substrate inhibition by ubiquinone could be involved in the pathogenesis of LHON, although Q 10 did not behave in the same way as its analogues with shorter side chains that were used in enzyme assays in the presence of the 3460/ND1-A52T mutation [15] . Congruently with this, we found higher enzyme activity for the Y59C mutant when endogenous ubiquinone Q 9 was used by the enzyme than with DB. Filling the binding cavity with the long isoprenoid tail of the Q 9−10 molecule could disable additional binding of ubiquinone, while the shorter tail structures of DB, Q 1 or Q 2 might allow the binding of another molecule, and high secondary binding affinity in some mutants could lead to the observed substrate inhibition. Despite the lack of substrate inhibition with endogenous ubiquinone, the phenomenon observed here may provide crucial information on the defect in these mutant enzymes under normal respiration conditions, which ultimately presents itself as LHON in humans. If short-chained ubiquinones present higher secondary binding affinities for the substrate in the long binding cavity, then endogenous ubiquinone will also be subject to stronger intermediate binding interaction within the substrate-binding cavity. This could lead to improper channelling of the enzyme for ubiquinone and, in parallel to the mutants, a lowering of the ubiquinone binding affinity. Both may lead to lower occupancy of the actual ubiquinone reduction site, with potentially disastrous consequences for the retinal ganglion cells, by promoting the production of ROS with consequent protein, lipid and DNA modification, impairment of energy production, and as a result, a higher probability of apoptosis. This hypothesis requires further testing, however. It is uncertain whether the altered ubiquinone interaction with complex I alone is sufficient for development of the disease, but the incomplete penetrance of the disease, gender bias, sudden onset of the symptoms and restriction of the affected tissue to a certain cell type are suggestive of other, currently unknown, genetic and/or environmental factors that could also be involved in the presentation of the disease.
In evaluating the effects of a pathogenic mtDNA mutation at the enzymatic level in a bacterial model, one of the main concerns must be the relevance of the results to mitochondrial disease. We compared the effects of NuoJ mutations in E. coli with human disease phenotypes caused by equivalent mutations and two LHON mutations in other subunits ( Table 5 ). The clinical phenotype variables evaluated were: first, the presence of other neurological manifestations in addition to LHON; secondly, disease penetrance and its dependence on gender in the affected families; and thirdly, the occurrence of visual recovery. This comparison shows that although LHON patients with M64V substitution in the ND6 subunit are less severely affected than patients with the Y59C or A72V mutations, no substantial difference in disease penetrance or its male predominance is detectable. The infrequent visual recovery and the occurrence of additional neurological symptoms in the Y59C and A72V mutations seem, however, to be linked to poorer complex I and/or NDH-1 activity. In addition, the DB-binding properties were more severely hampered in the E. coli homologues of the Y59C and A72V mutants than in M64V. The effects on the NDH-1 activity of E. coli mutations homologous with the ND6 substitutions M64V and A72V evidently coincide with to those occurring in the mitochondrion, and therefore it is reasonable to expect that this will also hold good for the Y59C mutation, for which no reports on complex I activity in the mitochondria of patients are currently available.
Replacement of Tyr 109 with phenylalanine was initially selected as a neutral control, but the surprising effects of this replacement on the ubiquinone affinity gave us other thoughts. In addition, the close proximity of Tyr 109 to the 14340/ND6-V112M mutation site associated with aminoglycoside-induced or non-aminoglycosiderelated sensorineural hearing impairment [43] suggests that this region is of functional significance. A double mutant M64V/ M72A was generated to examine whether a methionine residue in either of these positions is a prerequisite for proper complex I function. The background for this assumption was the observation that, whereas human ND6 has a methionine residue in position 64 and alanine residue at position 72, the highly homologous NDH-1 from the soil bacterium Paracoccus denitrificans has alanine in position 64 and methionine at position 72 in its equivalent subunit Nqo10 (Figure 1 ), while in NuoJ of E. coli, the model system used here, there are methionine residues in both positions 64 and 72. The respiratory defects caused by the single M64V and M72A mutations in NuoJ were not cumulative as expected, and the K m for DB was in the same range as for M64V and M72A. In contrast with the single M64V and M72V mutations, the double mutant did, however, show some tendency for substrate inhibition (Table 3) . Co-occurrence of the two mutations in the same protein domain seems to have more drastic effects on the enzyme than the occurrence of either mutant alone, as expected.
This bacterial model for LHON-associated mutations in the mtDNA gene of the ND6 subunit of complex I turned out to be a useful tool for analysing the effects of these mutations at the enzymatic level. This same approach is applicable to the study of other mtDNA mutations, including the rare ones, and may serve to reveal not only the mechanism underlying the pathogenesis of LHON but also the function of complex I. We hope that this model system will prove useful in the search of suitable therapeutic molecules or remedies for this disease.
